Exscientia Competitors and Similar CompaniesClear all

Exscientia's competitors and similar companies include Achilles Therapeutics, EUSA Pharma, Kheiron Medical and SOPHiA GENETICS.

	Exscientia Exscientia is a pharmatech company that utilizes artificial intelligence for small molecule drug discovery.	Achilles Therapeutics Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer.	EUSA Pharma EUSA Pharma is a biopharmaceutical company focused on oncology and rare diseases.	Kheiron Medical Kheiron Medical Technologies is a company that develops AI-driven mammography assessment solutions.	SOPHiA GENETICS SOPHiA GENETICS is a healthcare technology company focused on establishing the practice of data-driven medicine.
Founding Date	Founding Date 2012	Founding Date 2016	Founding Date 2015	Founding Date 2016	Founding Date 2011
Type	Type Subsidiary	Type Private	Type Private	Type Subsidiary	Type Public
Tags	Tags Technology artificial intelligence drug development oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Technology artificial intelligence data collection medical imaging medtech oncology	Tags Technology cloud services(SaaS)data automation data management healthtech medical diagnostics platform
Locations	Locations Oxford, GB HQ Wien, AT Osaka, JP Dundee, GB Miami, US	Locations London, GB HQ Stevenage, GB	Locations Hemel Hempstead, GB HQ	Locations London, GB HQ	Locations Rolle, CH HQ Bidart, FR Boston, US
Employees	Employees 88	Employees 695% decrease	Employees 965% decrease	Employees 215% decrease	Employees 423
Financial
Revenue (est.)	Revenue (est.) £20.1m (FY, 2023)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $65.2m (FY, 2024)
Cost of goods	Cost of goods £10.5m (FY, 2023)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $17.7m (FY, 2024)
Gross profit	Gross profit £10.8m (FY, 2023)	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit $47.6m (FY, 2024)
Net income	Net income (£146m) (FY, 2023)	Net income ($69.7m) (FY, 2023)	Net income N/A	Net income N/A	Net income ($62.5m) (FY, 2024)
Operating ⚠
Trademarks (US)	Trademarks (US) N/A	Trademarks (US) 3 (May, 2021)	Trademarks (US) N/A	Trademarks (US) N/A	Trademarks (US) 9 (FY, 2021)
Funding
Latest funding round	Latest funding round N/A	Latest funding round $ 121m (over 6 years ago)	Latest funding round $ 9.1m (almost 19 years ago)	Latest funding round N/A	Latest funding round N/A
Total funding raised	Total funding raised $ 430.2m	Total funding raised $ 138.1m	Total funding raised $ 54.2m	Total funding raised $ 22.1m	Total funding raised $ 245.8m